Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tuojie Biotech (Shanghai) Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units. SHI, GENBIN is the busiest examiner with 1 pending office action. This indicates that the company's current prosecution is diversified, with each application facing a unique examiner and art unit combination.
The involvement of 2 distinct examiners for 2 pending office actions means that there is no overlap in the individuals reviewing the company's current filings. For a practitioner, this requires managing 2 different examiner relationships simultaneously. Because the workload is also split between 2 distinct art units, the procedural requirements and timelines may differ for each of the 2 pending office actions.
SHI, GENBIN, identified as the busiest examiner with 1 pending office action, handles only half of the current pending workload. This decentralized structure in the Biotechnology & Pharmaceuticals area suggests that the company's patent strategy must be highly adaptable. The 2 distinct art units further diversify the potential prosecution outcomes for the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHI, GENBIN | 1 | — | — |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691820 | SUBSTITUTED 1,4-DIHYDRO-1,6-NAPHTHYRIDINE AMIDE AND USE THEREOF | SHI, GENBIN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691820 | SUBSTITUTED 1,4-DIHYDRO-1,6-NAPHTHYRIDINE AMIDE AND USE THEREOF | SHI, GENBIN | 1628 | §103§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18286536 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | — | Pending | Oct 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTuojie Biotech (Shanghai) Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Genbin Shi has the most, with 1 of Tuojie Biotech (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
